24,410 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Acquired by Eurizon Capital SGR S.p.A.

Eurizon Capital SGR S.p.A. bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the fourth quarter, Holdings Channel.com reports. The fund bought 24,410 shares of the biopharmaceutical company’s stock, valued at approximately $9,706,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in ALNY. Caitong International Asset Management Co. Ltd bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth approximately $29,000. Ameriflex Group Inc. bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth approximately $32,000. Aster Capital Management DIFC Ltd bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth approximately $36,000. Newbridge Financial Services Group Inc. bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth approximately $39,000. Finally, Eastern Bank bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth approximately $42,000. 92.97% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ALNY has been the topic of a number of research reports. Bank of America reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Thursday, February 12th. Freedom Capital upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 17th. Royal Bank Of Canada dropped their target price on shares of Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating on the stock in a report on Friday, May 1st. Chardan Capital reiterated a “buy” rating and issued a $425.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 25th. Finally, Wells Fargo & Company boosted their target price on shares of Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a report on Friday, May 1st. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $463.13.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $301.98 on Monday. Alnylam Pharmaceuticals, Inc. has a 52-week low of $284.28 and a 52-week high of $495.55. The company’s 50 day simple moving average is $309.38 and its 200-day simple moving average is $354.12. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. The firm has a market capitalization of $40.32 billion, a P/E ratio of 82.51 and a beta of 0.29.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The business had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same quarter in the previous year, the business earned ($0.44) earnings per share. The firm’s revenue was up 96.4% compared to the same quarter last year. As a group, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 7.36 EPS for the current year.

Insider Activity

In other news, EVP Pushkal Garg sold 1,775 shares of the business’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $319.74, for a total transaction of $567,538.50. Following the sale, the executive vice president owned 23,406 shares in the company, valued at $7,483,834.44. The trade was a 7.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Melissa Mclaughlin sold 2,286 shares of the company’s stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $330.42, for a total transaction of $755,340.12. Following the completion of the transaction, the insider owned 9,443 shares in the company, valued at approximately $3,120,156.06. This represents a 19.49% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 7,337 shares of company stock worth $2,370,087 over the last 90 days. 0.86% of the stock is owned by company insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.